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ABSTRACT
Objective: Plackett–Burman experimental design is used to identify the most important factors early in the experimentation phase when complete 
knowledge about the system is usually unavailable. The objective of this study was to screen out the most important factors affecting the size and 
entrapment efficiency of rivastigmine hydrogen tartrate (RHT) nanostructured lipid carriers (NLCs).
Methods: The RHT-loaded NLC was prepared by the modified solvent emulsification-diffusion method. The independent variables selected for 
Plackett–Burman design were drug: lipid ratio, solid lipid/liquid lipid (S/L) ratio, concentration Ryoto sugar ester (%w/v), the concentration of 
poloxamer 188 (%w/v), sonication time (min), sonication amplitude, and stirring time (h).
Results: The R2 value for the particle size equation was 86.16%. p value was (<0.05) 0.048 in case of sonication time. In case of entrapment efficiency, 
the R2 value was 87.12%. The p value (p<0.05) for S/L ratio and the Ryoto sugar (% w/v) was 0.028 and 0.042, respectively.
Conclusion: It can be concluded that sonication time has a significant effect on particle size, whereas S/L ratio and Ryoto sugar ester concentration 
have a significant effect on entrapment efficiency.
Keywords: Plackett–Burman, Rivastigmine, Nanostructured lipid carrier.
INTRODUCTION
Micro- and nano-drug delivery systems are developed to deliver the 
drug to desired tissue in human body, especially to a specific area or 
organ in a more stable and controlled way [1]. Nanotechnologies 
are beginning to change the scientific landscapes in terms of disease 
diagnosis, treatment [2]. All together to conquer these issues, a 
lot of hope has been centered on lipid-based carriers, for example, 
nanoemulsions (NEs) and nanostructured lipid carriers (NLCs) [3]. 
Nanoformulations are now continuously being researched for superior 
absorption, higher bioavailability, and greater therapeutic efficacy. 
Lipid-based nanoformulations have found much preference with the 
formulation scientist due to their relatively higher safety profile and 
enhancement of bioavailability [4]. Solid lipid nanoparticles (SLNs) 
and NLC have been introduced as potential attractive and marketable 
options due to their natural components [5]. The potential drawbacks of 
SLNs, such as limited drug loading capacity and drug expulsion during 
storage, can be avoided by the modifications that have been envisaged 
in NLCs [6]. In contrast to SLN, NLC is formed by controlling mixing of 
solid lipids with spatially incompatible liquid lipids. The incorporation 
of spatially incompatible liquid lipids to solid lipids leads larger 
distance between the fatty acid chain of the glycerides and general 
imperfection in the crystal [7]. This imperfect crystallization results in 
improved drug loading capacity and stable drug incorporation during 
storage [8]. The small size of the lipid particles ensures close contact 
with stratum corneum (SC)/membrane and can increase the amount of 
drug penetrating into mucosa or skin [9]. To resolve the experimental 
variables and interactions that have a major influence on the result 
with minimum possible runs and to determine the factors which would 
affect the quality of the product, a screening experiment was envisaged. 
In 1946, Plackett and Burman published a paper titled “the design 
of optimal multifactorial experiments” in Biometrika [10]. Plackett–
Burman design is a very competent screening design when only the 
major factors affecting the required output are to be considered. The 
Plackett–Burman design is superior to other screening designs, i.e., the 
fractional factorial design, the main effects are orthogonal and two-
factor interactions are partly confounded to the main effects. The aim 
of the present work was to find out the major variables that affect the 
particle size of NLC and entrapment efficiency of rivastigmine hydrogen 
tartrate in NLC (RHT-NLC).
MATERIALS AND METHODS
Materials
RHT was received as a gift sample from Torrent Pharmaceutical Ltd. 
(Mehsana, Gujarat, India). Compritol 888 ATO was a gift sample from 
Gattefosse Pvt. Ltd. (Mumbai, India). Ryoto sugar ester S-1670 was also 
a gift sample from Mitsubishi-Kagaku Foods Corporation (Tokyo, Japan). 
Triacetin was procured from SD Fine Chem Ltd., Mumbai, India. All 
other reagents were of analytical category and obtained from local 
commercial sources.
Solubility analysis
The saturation solubility of the drug was determined separately by adding 
an excess amount of drug to 2 mL each of the following oils triacetin, 
sesame oil, isopropyl myristate, canola oil, almond oil in tightly closed 
vials. The solutions were agitated for 24 h on a rotary shaker. The samples 
were centrifuged at 5000 rpm for 15 min and diluted appropriately to 
analyze the drug content through HPLC (Shimadzu, Millennium Column 
125 mm × 4.6 mm, mobile phase acetonitrile: buffer).
Preparation of NLC
A modified solvent emulsification-diffusion method was used for the 
preparation of NLC [11]. Solid lipid (Compritol 888 ATO) and liquid lipid 
(triacetin) were dissolved in 1:1 ethanol: chloroform mixture (2 mL) as 
the internal phase. The RHT (5 mg) was added to the above organic solvent 
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mixture. A lipid solution containing drug was dispersed gradually in the 
aqueous solution of sucrose stearate (Ryoto sugar ester S-1670, 8 mL) 
and sonicated (Ultrasonicator - Sartorius, Labsonic P, 3 sec interval). 
Thus, prepared primary emulsion was dispersed into aqueous 
poloxamer 188 solutions as a surfactant and stirred to remove the 
organic solvent from the continuous phase. The dispersion was 
centrifuged (18,000 RPM for 20 min) using Sartorius, Sigma 3-18K 
(Germany) to separate the RHT-NLCs. Thus, obtained NLCs were 
redispersed in an aqueous solution of Poloxamer 188 (1% w/v) and 
sonicated to get the RHT-NLCs.
Plackett–Burman design
The screening of factors was made with the help of Plackett–Burman 
design using Minitab 17. To screen out critical independent factors from 
among several factors, a few were shortlisted.
These variables were screened with 12 runs as per Plackett–Burman 
design (Table 1). Two levels of independent variables (high and low) 
were selected based on literature. Mean particle size and entrapment 
efficiency were selected as dependent variables.
Y=Ao+A1X1+A2X2+A3X3+A4X4+A5X5+A6X6+A7X7
Where, Y is the response, A0 is a constant, and A1–A7 are the coefficients 
of the response values (Tables 2 and 3).
Particle size
The particle size of RHT-NLCs was examined by photon correlation 
spectroscopy, in which light scattering fluctuations due to the Brownian 
movement were analyzed at a temperature of 25±1°C and a scattering 
angle of 90° using Zetasizer 1000 HS (Malvern Instruments, UK).
Entrapment efficiency
A fixed quantity (10 mL) of RHT-NLCs dispersion was centrifuged 
(18,000 RPM for 20 min). The supernatant was separated 
and analyzed for quantifying unencapsulated drug by HPLC. 
For the determination of the amount of drug in the sample, 
chromatographic separations were performed using HPLC 
(Shimadzu LC2010 CHT HPLC, Tokyo, Japan), which was equipped 
with Lichrospher reversed-phase C18 column (125 mm × 4.6 mm, pore 
size 5 µm). The mobile phases consisted of acetonitrile: ammonium 
phosphate (monobasic) buffer pH 5.6 (16:84 v/v). The flow rate was 
fixed at 1.0 mL/min and λmax was set at 217 nm. The drug entrapment 





Where, Wt is initial weight and was being weighted, of the drug in the 
supernatant.
RESULTS AND DISCUSSION
RHT is soluble in water, methanol, and ethanol, the pKa value is 8.85 
(strong base). The solubility of RHT was determined in various oils 
such as triacetin, sesame oil, isopropyl myristate, canola oil, and 
almond oil. The maximum solubility of RHT was found in triacetin. It 
is the triester of glycerol and acetylating agents (acetic acid and acetic 
anhydride). It is a colorless, viscous, and odorless liquid. Triacetin is 
soluble (in water) and an extremely weak basic (essentially neutral) 
compound (based on its pKa) [12]. Higher solubility of RHT in triacetin 
may be attributed to strong basic nature of RHT (Fig. 1).
RHT-NLCs were prepared by the modified solvent emulsification-
diffusion method. The particle size of the prepared formulation was 
found to vary between 218 and 458 nm. The particle size is very critical 
to the formulation of the nanoparticles. It determines the biological 
fate, toxicity, and targeting ability of this delivery system [13]. In 
addition, it can influence drug loading, drug release in vivo distribution, 
and stability of nanoparticles. The R2 value for particle size was found 
to be 86.16%. Sonication is the act of applying sound energy to agitate 
Table 1: The coded value of 1 and -1 as high and low values independent variables for Plackett–Burman design
Run Value of drug: lipid 
ratio












1 1 −1 1 −1 −1 −1 1
2 1 1 −1 1 1 −1 1
3 −1 −1 −1 −1 −1 −1 −1
4 −1 −1 −1 1 1 1 1
5 −1 1 −1 −1 −1 1 1
6 −1 −1 1 1 1 −1 1
7 1 1 1 −1 1 1 −1
8 1 −1 1 1 −1 1 −1
9 −1 1 1 1 −1 1 1
10 −1 1 1 −1 1 −1 −1
11 1 1 −1 1 −1 −1 −1
12 1 −1 −1 −1 1 1 1
Fig. 1: Chemical structure of (a) rivastigmine hydrogen tartrate 
and (b) triacetin
Fig. 2: Pareto chart of the standardized effect of various factors 
on particle size, (A) drug: lipid ratio, (b) solid lipid/liquid lipid 
ratio, (c) Ryoto sugar ester (%w/v), (d) poloxamer 188 (%w/v), 
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particles in a sample. Ultrasonication (>20 KHz) is a very valuable 
processing method in the production and application of nanosized 
materials. In general, ultrasonic cavitations increase polymerization 
and depolymerization reactions by momentarily dispersing a mass, 
increasing emulsification rates; improving diffusion rates; and 
producing greatly concentrated emulsions or uniform dispersions of 
micronized or nanosized materials. Sonication was done at 3 s interval 
because if sonication is continued without interruption for long periods 
of time, larger particles are reformed [14]. p value was established to 
be (p<0.05) 0.048 in case of sonication time, but for other factors, it 
was more than 0.05 (Fig. 2) which indicates that sonication time has a 
significant effect on particle size. The minimum particle size was found 
at 5 min of sonication time. It may be attributed to the aggregation 
of particles because the sufficient surfactant concentration was not 
available to form a protective layer on each nanoparticle [15].
Particle size = 95–368 drug lipid ratio +9.08 solid lipid: Liquid 
lipid ratio -49.8 ryoto sucrose stearate (% w/v) -38.8 poloxamer 
188 (% w/v) +19.10 sonication time +1.737 sonication amplitude 
+30.1 stirring time
In case of entrapment efficiency, the R2 value was found to be 87.12%. 
p value (<0.05) for solid lipid: Liquid lipid (S/L) ratio and Ryoto sugar 
(% w/v) was 0.028 and 0.042, respectively, which clearly indicates 
that both factors affect the entrapment efficiency significantly (Fig. 3). 
Liquid lipid is included in the NLC to increase the solubility of drug 
which, in turn, increases the entrapment of drug and avoids leakage. 
Sucrose esters are natural surfactant used as a penetration enhancer 
and controlled release matrix [16]. In the present study, Ryoto sucrose 
ester functions as a surfactant which helps in solubilizing the drug 
in lipid and dispersing the lipids in an aqueous solution to form a 
stable nanodispersion. As shown in Table 4, the highest entrapment 
efficiency was found in the case of the highest surfactant concentration. 
In most studies, a higher surfactant concentration leads to a smaller 
particle size and lower entrapment efficiency, but in this case, a higher 
solubilizing effect may have led to higher entrapment since Ryoto 
sucrose ester was used to solubilize the drug in lipid and to form a 
primary emulsion.
Entrapment efficiency = 40.9–15.0 drug lipid ratio +2.139 solid lipid: 
Liquid lipid ratio +11.17 sucrose stearate (%) -7.83 poloxamer 188–
1.167 sonication time -0.0233 sonication amplitude -0.25 stirring time
CONCLUSION
To find out critical parameters for preparation of stable NLCs, 
Plackett–Burman design was applied. The parameters that may 
affect the formulation were selected on the basis of a literature 
review. The study suggests the significance of controlling the critical 
formulation and process parameters during formulation as they 




Value of drug: lipid ratio - 0.1 0.2
Value of solid: liquid lipid - 3 9 
Sucrose ester (%w/v) %w/v 0.5 1.5
Poloxamer 188 (%w/v) %w/v 0.25 1.25
Sonication time Min 5 10
Sonication amplitude - 50 100
Stirring time h 1 3


































1 0.2 3 1.5 0.25 5 50 3 218±2.36 56.35±1.64
2 0.2 9 0.5 1.25 10 50 3 439±5.25 37.4±2.15
3 0.1 3 0.5 0.25 5 50 1 329±3.34 42.83±1.09
4 0.1 3 0.5 1.25 10 100 1 388±2.93 32.16±1.36
5 0.1 9 0.5 0.25 5 100 3 429±3.48 48.48±1.23
6 0.1 3 1.5 1.25 10 50 3 319±1.40 36.67±2.01
7 0.2 9 1.5 0.25 10 100 1 449±4.31 59.10±1.30
8 0.2 3 1.5 1.25 5 100 1 218±1.38 36.18±1.25
9 0.1 9 1.5 1.25 5 100 3 412±2.48 62.47±1.60
10 0.1 9 1.5 0.25 10 50 1 328±3.19 59.27±1.38
11 0.2 9 0.5 1.25 5 50 1 201±1.37 48.49±1.27
12 0.2 3 0.5 0.25 10 100 3 458±4.16 34.16±1.36
Mean ± S.D, n = 3
Fig. 3: Pareto chart of the standardized effect of various factors on 
entrapment efficiency, (a) drug: lipid ratio, (b) S/L ratio, (c) Ryoto 
sugar ester (%w/v), (d) poloxamer 188 (%w/v), (e) sonication 
time (min), (f) sonication amplitude, (g) stirring time (h)
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significantly influenced the final product, such as particle size and drug 
encapsulation efficiency. On the basis of the result, it can be concluded 
that for RHT-NLC the critical parameters were sonication time, S/L 
ratio, and Ryoto sugar ester (surfactant) concentration. Sonication 
time affects the particle size of NLC, whereas S/L ratio and Ryoto sugar 
ester concentration affect the entrapment efficiency of the formulation. 
Plackett–Burman design is a suitable screening method which can be 
utilized for other similar studies as well.
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